Parameter
| Biomarker | PHI | Full name | Prostate Health Index | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Susceptibility, diagnosis |
| Disease | PCa | Disease Subtypes | / | ||
| Organ | Prostate | Test Sample / Technology Platform | Serum (ELISA; RIA) | ||
| Pathobiological Mechanisms | It integrates measurements of three different forms of PSA to provide a composite score for more accurate assessment of a patient's risk of clinically significant prostate cancer. | ||||
| Clinical Availability Status | Clinical routine | ||||
| Notes and Dynamics | PHI demonstrates superior differentiation between prostate cancer and BPH with a 39% threshold. However, it remains dependent on PSA and cannot fully overcome some of PSA's limitations. | ||||